A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)
Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blinded, Placebo-controlled, Parallel, Multi-Center Phase II Clinical
Study to Evaluate the Efficacy and Safety of HY209 gel for Patients with Atopic Dermatitis